Related Experiment Video
Updated: Jul 1, 2026
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas
Jian Gu1, Che Zhang, Rongguang Chen
1Department of Pediatrics, Taihe Hospital Affiliated with the Yunyang Medical College, Shiyan, Hubei, 442000, China.
Abstract:
Extracellular matrix metalloproteinase inducer (EMMPRIN), a member of the immunoglobulin superfamily, is present on the surface of tumor cells where it stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPs). We have analyzed the clinicopathological characteristics of EMMPRIN and MMP2 expression in normal brain tissue and pediatric gliomas and evaluated their prognostic value in diagnosing the latter. Immunochemistry analysis revealed EMMPRIN and MMP2 expression in cryo-sections of pediatric gliomas (45 samples) and normal brain tissue (20 samples). Both EMMPRIN and MMP2 were expressed in normal brain and glioma tissues with different levels of malignancy. The intensively positive expression rates of EMMPRIN (22/27) and MMP2 (21/27) in anaplastic astrocytoma and glioblastoma tissues were significantly higher than those in normal brain and low-grade astrocytoma tissues (2/28 and (1/2)8, respectively). Spearman analysis indicated that the expression level of EMMPRIN was significantly positively correlated with that of MMP2 (r = 0.86, p < 0.01). The positive expression of EMMPRIN and MMP2 was associated with higher grade gliomas. Patients with EMMPRIN+/MMP2+ expression had the lowest survival rate (p < 0.01). Based on these results, we conclude that EMMPRIN and MMP2 are expressed differently in normal brain and pediatric gliomas. The detection of their co-expression may facilitate the prediction of pediatric gliomas prognosis.
Insights
Extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase 2 (MMP2) are expressed in pediatric gliomas. Their co-expression indicates higher tumor grade and poorer patient survival, aiding prognosis.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Extracellular matrix metalloproteinase inducer (EMMPRIN) is an immunoglobulin superfamily member on tumor cells.
- EMMPRIN stimulates fibroblasts to produce matrix metalloproteinases (MMPs), enzymes involved in tissue remodeling.
- Matrix metalloproteinase 2 (MMP2) is a key MMP implicated in tumor progression.
Purpose of the Study:
- To analyze the clinicopathological characteristics of EMMPRIN and MMP2 expression in pediatric gliomas.
- To evaluate the prognostic value of EMMPRIN and MMP2 expression in pediatric gliomas.
- To investigate the correlation between EMMPRIN and MMP2 expression levels and glioma grade.
Main Methods:
- Immunohistochemistry was used to detect EMMPRIN and MMP2 expression in pediatric glioma tissues (45 samples) and normal brain tissues (20 samples).
- Statistical analysis, including Spearman correlation, was performed to assess the relationship between EMMPRIN and MMP2 expression and clinicopathological features.
- Survival rates were analyzed in relation to EMMPRIN and MMP2 expression status.
Main Results:
- Both EMMPRIN and MMP2 were expressed in normal brain and glioma tissues, with varying levels of malignancy.
- Intensively positive expression rates of EMMPRIN and MMP2 were significantly higher in anaplastic astrocytoma and glioblastoma compared to normal brain and low-grade astrocytoma.
- EMMPRIN expression strongly correlated with MMP2 expression (r = 0.86, p < 0.01).
- Positive EMMPRIN and MMP2 expression was associated with higher-grade gliomas and the lowest patient survival rates (p < 0.01).
Conclusions:
- EMMPRIN and MMP2 exhibit differential expression patterns in normal brain tissue versus pediatric gliomas.
- The co-expression of EMMPRIN and MMP2 is linked to advanced tumor grade in pediatric gliomas.
- Detecting the co-expression of EMMPRIN and MMP2 may serve as a valuable prognostic marker for pediatric gliomas.